Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 2/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353825 | 0.69 | PARP1 (0.40) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL3655783 | 0.69 | ABCG2 (0.36) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL329447 | 0.69 | MAOA (0.46) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL8525523 | 0.69 | POLB (0.43) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL312107 | 0.69 | ABCG2 (0.36) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL11307666 | 0.69 | ABCG2 (0.36) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL329533 | 0.69 | ABCG2 (0.36) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL446185 | 0.69 | ABCG2 (0.36) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL3072276 | 0.69 | MAOA (0.46) | CA2ABCG2ITGB2ICAM1ITGAL | |
| SCHEMBL30094184 | 0.69 | BRD4 (0.41) | CA2ABCG2ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4196475-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20230167083-A1 | LANCL LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230128450-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-11597717-B2 | Substituted imidazoles as PLXDC2 ligands | LANDOS BIOPHARMA, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4118081-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-7956082-B2 | Indole derivative having PGD2 receptor antagonist activity | SHIONOGI & CO., LTD (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA | 2011-02-03 | — | — | US | disclosed |
| US-7842692-B2 | Azaindole derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | SHIONOGI & CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1939175-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi&Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1932839-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1916245-A1 | INDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONIST ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-30 | — | — | EP | disclosed |
| EP-1911759-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | Shionogi Co., Ltd. (JP) | 2008-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028717-A1 | AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, HRH2, PTGDR2 | CA2 679/4885ABCG2 785/4885ITGB2 2936/4885 |
| US-20230128450-A1 | NLRX1 LIGANDS | NLRP3, NLRP1, NOD1 | CA2 4482/4885ABCG2 2888/4885ITGB2 3226/4885 |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, CYSLTR1, CNR1 | CA2 490/4885ABCG2 1121/4885ITGB2 4340/4885 |
| US-20090197881-A1 | Azaindole Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, HRH2, PTGDR2 | CA2 815/4885ABCG2 846/4885ITGB2 2852/4885 |
| US-20230167083-A1 | LANCL LIGANDS | LANCL2, LANCL1, LCLAT1 | CA2 2569/4885ABCG2 2807/4885ITGB2 3933/4885 |
| US-20230192652-A1 | PLXDC2 LIGANDS | PLP2, PDCD1LG2, LCP2 | CA2 4849/4885ABCG2 3537/4885ITGB2 999/4885 |
| US-11597717-B2 | Substituted imidazoles as PLXDC2 ligands | PLK2, PLEC, PLP2 | CA2 4745/4885ABCG2 1929/4885ITGB2 1074/4885 |
| US-20090030014-A1 | Indole Derivative Having Pgd2 Receptor Antagonist Activity | HRH2, PTGDR, CNR2 | CA2 531/4885ABCG2 320/4885ITGB2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.